Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Oncologist. 2022 May 6;27(5):352-362. doi: 10.1093/oncolo/oyac047.
Circulating biomarkers have emerged as valuable surrogates for evaluating disease states in solid malignancies. Their relative ease of access and rapid turnover has bolstered clinical applications in monitoring treatment efficacy and cancer progression. In this review, the roles of various circulating biomarkers in monitoring treatment response are described. Non-specific markers of disease burden, tumor markers (eg CA 125, CEA, PSA, etc.), circulating tumor cells, nucleic acids, exosomes, and metabolomic arrays are highlighted. Specifically, the discovery of each of these markers is reviewed, with examples illustrating their use in influencing treatment decisions, and barriers to their application noted where these exist. Finally, opportunities for future work using these circulating biomarkers are discussed.
循环生物标志物已成为评估实体恶性肿瘤疾病状态的有价值的替代物。它们相对容易获取和快速转化，增强了在监测治疗效果和癌症进展方面的临床应用。在这篇综述中，描述了各种循环生物标志物在监测治疗反应中的作用。非特异性疾病负担标志物、肿瘤标志物（例如 CA125、CEA、PSA 等）、循环肿瘤细胞、核酸、外泌体和代谢组学阵列被强调。具体而言，回顾了每种这些标志物的发现，并举例说明了它们在影响治疗决策中的应用，以及在存在这些应用障碍的情况下注意到的应用障碍。最后，讨论了使用这些循环生物标志物进行未来工作的机会。
